Therapeutic | Ublituximab |
Target | MS4A1 |
Heavy Chain | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS |
Light Chain | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | EMABling Platform |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | LFB Biotechnologies, rEVO Biologics, Johns Hopkins University, TG Therapeutics Inc |
Conditions Approved | na |
Conditions Active | Chronic lymphocytic leukaemia, Multiple sclerosis, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Non-Hodgkin's lymphoma, Neuromyelitis optica |
Conditions Discontinued | na |
Notes |